Literature DB >> 17043351

Clinicopathologic characteristics and outcome of diffuse large B-cell lymphomas presenting with an associated low-grade component at diagnosis.

Hervé Ghesquières1, Françoise Berger, Pascale Felman, Evelyne Callet-Bauchu, Paul-André Bryon, Alexandra Traverse-Glehen, Catherine Thieblemont, Lucile Baseggio, Anne-Sophie Michallet, Bertrand Coiffier, Gilles Salles.   

Abstract

PURPOSE: Some diffuse large B-cell lymphomas (DLBCL) present at diagnosis with associated morphologic features of small B-cell non-Hodgkin's lymphoma (NHL) and may arise from the transformation of a previously unknown indolent low-grade lymphoma. The characteristics and prognosis of these particular DLBCL are not well known. PATIENTS AND METHODS: The strict morphologic review of consecutive DLBCL patients diagnosed over 12 years in our department (Hematology Department, Centre Hospitalier Lyon-Sud, Lyon, France) allowed to retrieve 60 DLBCL that could be have occurred from the transformation of marginal zone B-cell NHL (32 patients), follicular NHL (22 patients), and small lymphocytic NHL (6 patients). We compared them to 180 matched patients of de novo DLBCL.
RESULTS: Patients median age was 55 years and presented the following clinical characteristics: poor performance status in 33%, disseminated disease in 97%, more than one extranodal site in 50%, and increased lactate dehydrogenase level in 55%. Complete remission with multidrug chemotherapy regimens was achieved in 60% of the patients, but 48% relapsed: 28% with aggressive and 20% with indolent histology, respectively. Overall survival (OS) and freedom-from-progression rates at 5 years were 57% and 33%, respectively. The matched-control analysis showed that patients with transformed NHL at diagnosis had lower complete response to chemotherapy (P = .004) and higher progression rate (P = .03), whereas no difference was observed in OS (P = .21).
CONCLUSION: Compared to de novo DLBCL, transformed NHL at diagnosis have similar overall survival but lower complete response to initial treatment and higher risk of indolent relapses.

Entities:  

Mesh:

Year:  2006        PMID: 17043351     DOI: 10.1200/JCO.2006.07.5671

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  21 in total

Review 1.  Treatment options for transformed lymphoma: incorporating allogeneic stem cell transplantation in a multimodality approach.

Authors:  Nishitha Reddy; Bipin N Savani
Journal:  Biol Blood Marrow Transplant       Date:  2011-05-11       Impact factor: 5.742

Review 2.  FDG PET-CT in follicular lymphoma: a case-based evidence review.

Authors:  Stephen D Smith; Mary Redman; Kieron Dunleavy
Journal:  Blood       Date:  2014-12-19       Impact factor: 22.113

3.  Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS).

Authors:  Nina D Wagner-Johnston; Brian K Link; Michelle Byrtek; Keith L Dawson; John Hainsworth; Christopher R Flowers; Jonathan W Friedberg; Nancy L Bartlett
Journal:  Blood       Date:  2015-06-23       Impact factor: 22.113

Review 4.  Clonal relationship of marginal zone lymphoma and diffuse large B-cell lymphoma in Sjogren's syndrome patients: case series study and review of the literature.

Authors:  Vadim Romanovich Gorodetskiy; Natalya Alexandrovna Probatova; Stefka Gospodinova Radenska-Lopovok; Natalya Valerievna Ryzhikova; Yulia Vladimirovna Sidorova; Andrey Borisovich Sudarikov
Journal:  Rheumatol Int       Date:  2019-11-09       Impact factor: 2.631

5.  Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphoma.

Authors:  Yucai Wang; Brian K Link; Thomas E Witzig; Matthew J Maurer; Cristine Allmer; Rebecca L King; Andrew L Feldman; Thomas M Habermann; Stephen M Ansell; Susan L Slager; James R Cerhan; Grzegorz S Nowakowski
Journal:  Blood       Date:  2019-10-17       Impact factor: 22.113

6.  The NOTCH pathway is recurrently mutated in diffuse large B-cell lymphoma associated with hepatitis C virus infection.

Authors:  Luca Arcaini; Davide Rossi; Marco Lucioni; Marta Nicola; Alessio Bruscaggin; Valeria Fiaccadori; Roberta Riboni; Antonio Ramponi; Virginia V Ferretti; Stefania Cresta; Gloria Margiotta Casaluci; Maurizio Bonfichi; Manuel Gotti; Michele Merli; Aldo Maffi; Mariarosa Arra; Marzia Varettoni; Sara Rattotti; Lucia Morello; Maria Luisa Guerrera; Roberta Sciarra; Gianluca Gaidano; Mario Cazzola; Marco Paulli
Journal:  Haematologica       Date:  2014-11-07       Impact factor: 9.941

Review 7.  Central nervous system prophylaxis in non-Hodgkin lymphoma: who, what, and when?

Authors:  Chan Yoon Cheah; John F Seymour
Journal:  Curr Oncol Rep       Date:  2015-06       Impact factor: 5.075

8.  Bone marrow involvement in diffuse large B-cell lymphoma: correlation between FDG-PET uptake and type of cellular infiltrate.

Authors:  Gaetano Paone; Emmanuel Itti; Corinne Haioun; Philippe Gaulard; Jehan Dupuis; Chieh Lin; Michel Meignan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-12-19       Impact factor: 9.236

9.  IgG4-producing lymphoma arising in a patient with IgG4-related disease.

Authors:  Takuro Igawa; Toshiaki Hayashi; Kazuya Ishiguro; Yumiko Maruyama; Mai Takeuchi; Katsuyoshi Takata; Tadashi Yoshino; Yasuharu Sato
Journal:  Med Mol Morphol       Date:  2016-04-11       Impact factor: 2.309

10.  Superior long-term outcome of patients with early transformation of non-Hodgkin lymphoma undergoing stem cell transplantation.

Authors:  Nishitha Reddy; Olalekan Oluwole; John P Greer; Stacey Goodman; Brian Engelhardt; Madan H Jagasia; Bipin N Savani
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2012-09-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.